The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT). Materials and Methods Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were assessed for the role of FGFR4 genotype on treatment response and survival. Results A total of 94 patients were homozygous for the Gly388 allele, and 110 were heterozygous and 40 homozygous for the Arg388 allele. No significant association was found between the FGFR4 genotype and clinicopathological parameters. However, patients carrying the Gly388 allele showed a better overall response rate than Arg388 carriers (p=0.038). In addition, Gly388 allele patients at an earlier stage showed better overall survival (OS) and progression-free survival than Arg388 carriers. Among these, the Gly388 allele showed sig- nificantly improved OS compared to Arg388 carriers in the lymph node (LN) metastasis group (p=0.042) compared to the no LN metastasis group (p=0.125). However, similar sur- vival outcomes were observed for advanced-stage disease regardless of genotype. Conclusion This result suggests that the role of FGFR4 Gly388 in treatment outcomes differs according to esophageal cancer stage. It showed a predictive role in the response of esophageal can- cer patients to CRT with a better trend for OS in Gly388 than Arg388 carriers in the early stages. In particular, LN-positive early-stage patients carrying the Gly388 allele showed improved OS compared to those carrying Arg388.
Abstract
Purpose The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT). Materials and Methods Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were assessed for the role of FGFR4 genotype on treatment response and survival. Results A total of 94 patients were homozygous for the Gly388 allele, and 110 were heterozygous and 40 homozygous for the Arg388 allele. No significant association was found between the FGFR4 genotype and clinicopathological parameters. However, patients carrying the Gly388 allele showed a better overall response rate than Arg388 carriers (p=0.038). In addition, Gly388 allele patients at an earlier stage showed better overall survival (OS) and progression-free survival than Arg388 carriers. Among these, the Gly388 allele showed sig- nificantly improved OS compared to Arg388 carriers in the lymph node (LN) metastasis group (p=0.042) compared to the no LN metastasis group (p=0.125). However, similar sur- vival outcomes were observed for advanced-stage disease regardless of genotype. Conclusion This result suggests that the role of FGFR4 Gly388 in treatment outcomes differs according to esophageal cancer stage. It showed a predictive role in the response of esophageal can- cer patients to CRT with a better trend for OS in Gly388 than Arg388 carriers in the early stages. In particular, LN-positive early-stage patients carrying the Gly388 allele showed improved OS compared to those carrying Arg388.
참고문헌 (24)
- Siegel R, "Cancer statistics, 2012", CA Cancer J Clin, 62, pp.10~29 (2012)
- 김대은, "Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated after Definitive Chemoradiotherapy", Cancer Research and Treatment, 45(4), pp.276~284 (2013), 대한암학회[DOI]
- Shim HJ, "A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer", Cancer Chemother Pharmacol, 70, pp.683~690 (2012)
- Kelsey CR, "Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer", Int J Radiat Oncol Biol Phys, 69, pp.770~776 (2007)
- Hong TS, "Targeted therapies with chemoradiation in esophageal cancer: development and future directions", Semin Radiat Oncol, 23, pp.31~37 (2013)
- Paraiso KH, "Fibroblast-mediated drug resistance in cancer", Biochem Pharmacol, 85, pp.1033~1041 (2013)
- Yang F, "FGFR1 is essential for prostate cancer progression and metastasis", Cancer Res, 73, pp.3716~3724 (2013)
- Tran TN, "Fibroblast growth factor receptor 1(FGFR1)copy number is an independent prognostic factor in non-small cell lung cancer", Lung Cancer, 81, pp.462~467 (2013)
- Ma Z, "Polymorphisms of fibroblast growth factor receptor 4have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population", Int J Cancer, 123, pp.2574~2579 (2008)
- Spinola M, "Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients", J Clin Oncol, 23, pp.7307~7311 (2005)
- Thussbas C, "FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer", J Clin Oncol, 24, pp.3747~3755 (2006)
- Ansell A, "Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer", Oral Oncol, 45, pp.23~29 (2009)
- Dutra RL, "FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx", PLoS One, 7, pp.50747~ (2012)
- Wesche J, "Fibroblast growth factors and their receptors in cancer", Biochem J, 437, pp.199~213 (2011)
- Greulich H, "Targeting mutant fibroblast growth factor receptors in cancer", Trends Mol Med, 17, pp.283~292 (2011)
- Katoh M, "FGF receptors : cancer biology and therapeutics", Med Res Rev, 34, pp.280~300 (2014)
- Taylor JG 6th, "Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models", J Clin Invest, 119, pp.3395~3407 (2009)
- Ye Y, "The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression", Ann Surg Oncol, 17, pp.3354~3361 (2010)
- Liu R, "FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer", Cancer Res, 73, pp.5926~5935 (2013)
- Pelaez-Garcia A, "FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer", PLoS One, 8, pp.63695~ (2013)
- Heinzle C, "Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis", Cancer Res, 72, pp.5767~5777 (2012)
- Gordon MA, "Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation", Pharmacogenomics, 7, pp.67~88 (2006)
- Sugiyama N, "FGF receptor-4(FGFR4)polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex", Proc Natl Acad Sci U S A, 107, pp.15786~15791 (2010)
- Ye YW, "Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer", Oncol Rep, 30, pp.2777~2784 (2013)